Rex Fang & Innovation Equity Premium Income ETF vs Globus Medical Inc. Class A Common Stock — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.82 (market cap $753.07M), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 13.6× Rex Fang & Innovation Equity Premium Income ETF's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rex Fang & Innovation Equity Premium Income ETF for 57 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| FEPI | GMED | |
|---|---|---|
Market Cap | $753.07M | $10.25B |
Volume | 329,956 | 1,059,528 |
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $96.82 |
52-Week Low | $37.98 | $58.33 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $9.76B |
Signals from Pluang's Aura AI — not financial advice
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $43.28, showing minimal daily movement with a 0.14% gain. The ETF employs a covered call strategy on AI and mega-cap tech stocks, generating substantial weekly dividends averaging $0.20-0.21 per share. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. Recent news highlights FEPI's 25% yield but notes underperformance compared to peers in total returns.
FEPI offers high income potential through its covered call strategy but faces capped upside and concentrated tech exposure risks. The ETF's performance depends heavily on AI sector volatility and options pricing efficiency. While attractive for income-focused investors, total return potential may lag broader market indices during strong bull markets.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →